Late-stage clinical trials evaluating personalized cancer vaccines combined with checkpoint inhibitors have met primary endpoints. Results indicate a statistically significant reduction in disease recurrence compared to monotherapy.
Manufacturing Logistics and Delivery Timelines
The logistical challenge of sequencing patient tumors and manufacturing custom mRNA sequences within a 30-day window remains substantial. Health systems are investing in automated bio-manufacturing nodes to decentralize production.